← Avalyn Pharma Inc. (AVLN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Avalyn Pharma Inc. (AVLN)
Pharmaceutical Preparations · market cap $1.3B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Avalyn Pharma Inc. (AVLN) is a small-cap clinical-stage pharma (50 employees, ~$1.26B market cap) focused on pulmonary fibrosis, with two Phase 2 assets: AP01 targeting pulmonary fibrosis broadly and AP02 targeting idiopathic pulmonary fibrosis (IPF) specifically. The company carries $92.3M in cash against a ~9.3-month runway, with the next major data readout for AP02 expected December 2025 and AP01 mid-2027.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · AP02imp 7/10
- 2027-06-15 (est.)Phase 2 · AP01imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AP01 | Phase 2 | Pulmonary Fibrosis |
| AP02 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) |
Price & technical context
3-month
-7.8%
6-month
—
12-month
—
52-wk range
$25.68–$39.25
vs 50-day MA
-17.7%
vs 200-day MA
—
Realized vol
64.7%
Max drawdown
-31.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AVLN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.